JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB198557

HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017]

Be the first to review this product! Submit a review

|

(1 Publication)

Rabbit Recombinant Monoclonal Retinoic Acid Receptor beta antibody - conjugated to HRP. Suitable for IHC-P, WB and reacts with Human samples. Cited in 1 publication.

View Alternative Names

HAP, NR1B2, RARB, Retinoic acid receptor beta, RAR-beta, HBV-activated protein, Nuclear receptor subfamily 1 group B member 2, RAR-epsilon

2 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (AB198557)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (AB198557)

IHC image of Retinoic Acid Receptor beta staining in a section of formalin-fixed paraffin-embedded human normal kidney*. The section was pre-treated using pressure cooker heat mediated antigen retrieval with sodium citrate buffer (pH6) for 30mins, and incubated overnight at +4°C with ab198557 at 1/50 dilution. DAB was used as the chromogen (ab103723), diluted 1/100 and incubated for 10min at room temperature. The section was counterstained with haematoxylin and mounted with DPX. The inset negative control image is taken from an identical assay without primary antibody.

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

Western blot - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (AB198557)
  • WB

Lab

Western blot - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (AB198557)

This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab198557 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

All lanes:

Western blot - HRP Anti-Retinoic Acid Receptor beta antibody [EPR2017] (ab198557) at 1/5000 dilution

Lane 1:

MCF-7 (Human breast adenocarcinoma cell line) Whole Cell Lysate at 10 µg

Lane 2:

Daudi (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg

Lane 3:

U-87 MG (Human glioblastoma astrocytoma) Whole Cell Lysate at 10 µg

Predicted band size: 50 kDa

Observed band size: 55 kDa

true

Exposure time: 3min

  • Unconjugated

    Anti-Retinoic Acid Receptor beta antibody [EPR2017]

  • Carrier free

    Anti-Retinoic Acid Receptor beta antibody [EPR2017] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR2017

Isotype

IgG

Conjugation

HRP

Excitation/Emission
Carrier free

No

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/50", "IHCP-species-notes": "<p></p> Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/5000", "WB-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Retinoic Acid Receptor beta (RARβ) also known as NR1B2 is a nuclear receptor with a molecular mass of approximately 51 kDa. This receptor functions mechanically by binding retinoic acid which induces conformational changes that allow it to regulate gene transcription. RARβ is expressed in various tissues including the central nervous system lungs and kidneys. Its role as a transcription factor influences gene expression patterns by interacting with specific retinoic acid response elements (RARE) in the DNA.
Biological function summary

Retinoic Acid Receptor beta plays a significant role in cell differentiation and development. It often forms heterodimers with retinoid X receptors (RXRs) to execute its functions. This interaction enhances the receptor's ability to modulate gene expression. The complex orchestrates a broad range of developmental processes particularly in embryogenesis and organogenesis. RARβ influences several cellular activities including the regulation of apoptosis and the maintenance of cellular homeostasis.

Pathways

The activity of Retinoic Acid Receptor beta integrates predominantly into the retinoic acid signaling pathway and the Wnt signaling pathway. Through these pathways RARβ contributes to the regulation of cell fate and the inhibition of cell proliferation. It functions alongside proteins such as RXRs in the retinoic acid pathway and may interact with components of the Wnt pathway like β-catenin to control gene transcription and cellular responses. These interactions guide various developmental and physiological processes.

Retinoic Acid Receptor beta has connections to cancer and retinal diseases. Changes in RARβ expression and function associate with several types of cancer including lung and breast cancer often involving dysregulation of apoptosis and cell proliferation. In retinal diseases RARβ in conjunction with the protein CRABP (cellular retinoic acid-binding protein) affects the homeostasis and survival of retinal cells. Understanding RARβ's role in these diseases helps in developing targeted therapies aimed at modulating its activity.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. The RXR/RAR heterodimers bind to the retinoic acid response elements (RARE) composed of tandem 5'-AGGTCA-3' sites known as DR1-DR5. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to corepressors (PubMed : 12554770). The RXRA/RARB heterodimer can act as a repressor on the DR1 element and as an activator on the DR5 element (PubMed : 29021580). In concert with RARG, required for skeletal growth, matrix homeostasis and growth plate function (By similarity).
See full target information RARB

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Molecular medicine reports 14:3602-8 PubMed27599527

2016

Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Hong-Yue Ren,Bo Chen,Gui-Li Huang,Yu Liu,Dong-Yan Shen
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com